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Quality of life scores 
should be compared be-
fore and after patients 
have undergone dialysis 
To the Editor: We intention-
ally read the article “Quality of life 
(QoL) in hemodialysis and peri-
toneal dialysis patients in Saudi” 
written by Wakeel et al with great 
interest.1 They concluded that the 
quality of life (QoL) was better 
among peritoneal dialysis (PD) 
than hemodialysis (HD) patients in 
all domains except physical domain. 
PD patients spent more quality 
time and were more satisfied than 
HD patients.1
 In the last years, advances in 
dialysis procedures and new guide-
lines to treat the chronic renal fail-
ure patients have improved their 
treatment and prolonged their 
lives. At the same time, the con-
cept of health-related quality of life 
(HRQoL) strengthened as a new 
goal to be achieved. The current 
dialysis guidelines enforce treat-
ments to achieve similar outcomes 
in the long run, independently of 
the choice of dialysis treatment.2 
Manns et al. in their study con-
cluded that there was no significant 
difference in HRQoL for prevalent 
end-stage renal disease patients 
treated with HD or PD.3 In another 
study, Wu et al. concluded that that 
PD did not seem to produce a bet-
ter QoL than HD for patients who 
imitated renal replacement thera-
py.4 Ginieri-Coccossis. et al. in their 
study concluded that the results 
provided evidence that patients in 
HD treatment modality, particu-
larly those with many years of treat-
ment, experienced a more compro-
mised QoL in comparison to PD 
patients.5 The results may change 
due to sociodemographic character-
istics of patients. We think that the 
comparison of the two groups could 
be more meaningful if the QoL is 
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measured before and after patients 
are undergone dialysis. Another 
point of discussion could be that 
the variations in study results may 
vary upon longer follow-up dura-
tions of these patients.
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Reply: Oxytocin amelio-
rates cisplatin-induced 
nephrotoxicity in Wistar 
rats
To the Editor: We read with 
great interest the recently pub-
lished nice article in the esteemed 
“Ann Saudi Med”, by Elberry et 
al entitled “Oxytocin ameliorates 
cisplatin-induced nephrotoxicity 
in Wistar rats”.1 In an experimen-
tal study on 48 male Wistar albino 
rats, Elberry et al. aimed to study 
the ameliorative effects of oxyto-
cin against cisplatin renal toxicity.1 
They assessed the renal injury of 
cisplatin by performing histopath-
ological study and by observing an 
increase in serum LDH activity as 
well as urea and creatinine levels. 
Furthermore, to asses renal injury, 
they also measured renal tissue 
activities of catalase, superoxide 
dismutase, glutathione peroxidase, 
and glutathione S-transferase as 
well as glutathione level. Also the 
renal tissue content of thiobarbi-
turic acid–reactive substances, ni-
tric oxide end-product nitrite, and 
the activity of myeloperoxidase 
were measured. They found that 
oxytocin protected rats from cis-
platin-induced nephrotoxicity and 
attributedthis to the antioxidant 
activity of oxytocin.1 In this letter, I 
would like to point out a few points 
about cisplatin nephrotoxicity. In a 
preclinical study, we observed that 
estrogen attenuates the defending 
property of erythropoietin against 
cisplatin-induced renal toxicity in 
ovariectomized Wistar rats.2 We 
also observed that L-arginine had 
ameliorative effects against cispla-
tin-induced renal toxicity in male 
rats. Nevertheless, it intensifies 
the induced injury in female rats.3 
In this study, we described a sex-
related difference in the rat model 
of cisplatin nephrotoxicity.3 Since, 
the position of gender in cispla-
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tin-induced renal toxicity is not 
reported from published reports, 
we conducted another preclinical 
study on the rat model of cisplatin 
nephrotoxicity. From the results of 
this study we found that losartan, 
as an angiotension receptor blocker, 
may prevent cisplatin nephrotoxic-
ity in males, whereas it aggravates 
the cisplatin-induced tubular injury 
in female rats.4 We concluded that 
the sex-related difference of cispla-
tin nephrotoxicity may be related 
to the renin–angiotensin system 
receptors in the kidneys.4-9 In ad-
dition, we reported that, Vitamin 
E, Vitamin C, or losartan have 
not ameliorative effects against 
cisplatin-induced renal toxicity 
in the presence of estrogen in the 
ovariectomized rat model of cis-
platin toxicity,10 which is in agree-
ment with our previous results. 
Therefore, it is well established that 
there is a gender difference in the 
cisplatin-induced renal toxicity in 
the rat model. However, it is well 
recognized that some conditions 
leading to chronic kidney diseases 
are gender related too.5-9 Few stud-
ies published regarding gender dif-
ference in cisplatin-induced kidney 
toxicity. However, there still needs 
to more investigate mechanisms 
interact in cisplatin nephrotoxicity 
especially on gender difference.10,11 
To better find the factor of sex dif-
ference in cisplatin nephrotoxicity, 
further experimental rat model or 
clinical studies recommended.
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Fertility outcome of using 
intrauterine balloon stent-
ing during resectoscopic 
septum division
To the Editor: With a great inter-
est, I have read a recently published 
article in Annals of Saudi Medicine 
by Basim Fuad Abu Rafea et al, 
entitled “Fertility and pregnancy 
outcomes following resectoscopic 
septum division with and without 
intrauterine balloon stenting: a 
randomized pilot study”.1 The au-
thors skillfully declared an interest-
ing investigation about the benefits 
of intrauterine balloon splinting/
Foley catheter after resectoscopic 
septum division on fertility, sep-
tum reformation, and pregnancy 
outcomes. They concluded that 
“Following resectoscopic septum 
division with monopolar knife 
electrode, splinting the uterine cav-
ity with Foley catheter provided no 
advantage in clinical pregnancy rate, 
septum reformation, and pregnancy 
outcomes.” Although this issue is 
a challenging topic in fertility and 
pregnancy, but there are some con-
cerns in the mentioned study that 
undermine the reported findings to 
make a definite conclusion.
The number of cases included 
in the study is one of the most dis-
cussed queries. I can declare that if 
the difference between the 2 studied 
groups (balloon or no balloon) was 
not significant, it could due to the 
small amount of sample size that 
did not allow drawing any defini-
tive conclusions. Thus, to rule out 
this query and to compensate any 
refusal of data, the authors should 
estimate the “power” of their study. 
The authors randomized the pa-
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tients into the 2 studied groups, and 
no significant difference in terms of 
age, parity, and comorbidities were 
reported. However, menopausal 
status, race, age of menopause, 
menopausal hormone therapy, oc-
cupation, marital status, OCP use, 
and so on, should be distributed 
equally between the 2 groups before 
drawing any conclusion, which was 
not considered by the authors in 
this study. 
The authors expertly excluded 
those patients who received pre-
operative endometrial thinning, 
adjunctive postoperative hormone 
therapy, or antibiotic prophylaxis, 
but they seemed to be inadequate 
as exclusion criteria in the clinical 
study. The authors did not declare 
if they excluded pregnant women, 
patients with active pelvic infection, 
patients allergic to radiographic 
contrast media, and patients with or 
without known endometrial or cer-
vical cancer.2,3 Therefore, the men-
tioned criteria should be considered 
by the authors. A participation fel-
low chart is mandatory for clinical 
studies based on the CONSORT 
(Consolidated Standards of 
Reporting Trials) statement,4,5 
but it was missing in this study. 
Moreover, in the ”Methods” sec-
tion, the statistical analysis is poorly 
presented and the power analysis 
is incomplete. Moreover, the cho-
sen proportion for significant or 
not significant difference in fertility 
and pregnancy outcomes should be 
mentioned. Finally, the secondary 
outcomes of the resectoscopic pro-
cedure, such as fever, increasing ab-
dominal pain, heavy vaginal bleed-
ing, foul smelling vaginal discharge,6 
and so on, should be mentioned in 
the results by the authors. 
We suggest that a study with 
accurate and powerful methods ac-
cording to CONSORT statement 
is required for this topic. However, 
the authors acknowledged to the 
heterogeneity of their study popu-
lation as a limitation. Therefore, 
future studies with a homogeneous 
sample, well-characterized controls, 
and cases that increase the sensi-
tivity of detecting the associations 
should be considered necessary to 
exclude this problem. 
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Prevalence of celiac dis-
ease in healthy Iranian 
school children
To the Editor: I have two com-
ments on the interesting study by 
Dehghani et al.1 
First, Dehghani et al1 stated in 
their study that the prevalence of 
celiac disease (CD) based on anti-
tissue transglutaminase antibodies 
(tTGA) screening test was 1:50, 
whereas the prevalence of biopsy-
proven CD (silent celiac) was 1:167. 
I presume that the actual prevalence 
is higher. This is based on the fol-
lowing contributory factors: (1) 
The consumption of wheat as a ma-
jor dietary staple is still a major cus-
tom in Iran. (2) Consanguineous 
marriage is a prevailing practice in 
Iran with the first cousin marriage 
being the most common type of 
consanguinity (69%).2 (3) Iran is 
a multiethnic country and, there-
fore, genetic variance does exist in 
the Iranian population. (4) There 
is inadequate awareness of the re-
ferring pediatricians with regard 
to the uncommon manifestations 
of CD. (5) Underdiagnosis of CD 
in the primary care setting is often 
compounded by disease misman-
agement. (6) CD is strongly associ-
ated with HLA-DQ2 in developing 
countries. Though recent studies 
are not yet present on HLA phe-
notypes in Iranians, the available 
data has pertained to the potential 
role of HLA-DQ2 in increasing the 
propensity of certain populations 
in Asia like Iran to have CD.3 (7) 
Iranians might follow the general 
trend of overall worldwide increase 
in the CD prevalence, including si-
lent cases.
Second, to meet the principles of 
screening, a disease must be com-
mon, and a significant health bur-
den must be detectable and treat-
able. I presume that screening for 
CD in Iranian children seems justi-
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points: (1) There is substantial prev-
alence of CD, in particular, silent 
cases in Iran.1,4  (2) Undiagnosed 
CD patients have long-term serious 
health consequences, including ma-
lignancy, anemia, short stature, os-
teopenia, and infertility. Moreover, 
the medical costs and utilization 
of selected health care services over 
time for symptomatic CD patients 
during the delay between symptoms 
onset and diagnosis are substantial. 
(3) There is the presence of effec-
tive screening tool for CD in terms 
of measuring the serum tTGA 
supplemented whenever necessary 
by small intestinal biopsy. (4) There 
is the presence of effective therapy 
for CD in terms of gluten-free diet. 
The children’s age range supposed 
to undergo screening for CD ought 
to be determined in Iran. However, 
the available evidence has advocated 
the age 2 to 3 years as the best time 
for measuring the serum tTGA due 
to the high detection rate.5
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The reliability of palatal 
rugoscopy in forensic 
identification 
To the Editor: There is paucity 
of information about the reliabil-
ity of palatal rugoscopy in forensic 
identification in Saudi Arabia. As 
you know, forensic dental identifica-
tion plays an important role in the 
establishment of a person’s indi-
viduality, and forensic odontology 
deals with the proper handling and 
examination of dental evidence and 
the proper evaluation and presenta-
tion of dental findings in the inter-
est of justice.1 Palatal rugoscopy is 
the study of palatal rugae, and their 
uniqueness to individuals can pro-
vide a reliable source of identifica-
tion.2 Palatal rugae are irregular, 
asymmetric ridges of mucous mem-
brane extending lateral from the in-
cisive papilla and the anterior part 
of the median palatal raphe.3 Palatal 
rugae are well protected by the lips, 
cheek, and tongue and are thus pro-
tected from external insults such as 
fire and high-impact trauma. They 
do not change shape with age and 
reappear after trauma or surgical 
procedures. 
From the recent studies done in 
the Indian population, it was postu-
lated that palatal rugae can be used 
as a personal soft-tissue oral print in 
forensic identification.4,5 The rugae 
pattern can be recorded by means of 
dental impressions and casts made 
from them. The study of maxillary 
dental casts is the most widely used 
technique due to its simplicity, cost, 
and reliability. The overlay print of 
palatal rugae in a maxillary cast can 
be used to perform a comparative 
analysis. Computerized recording 
of the palatal rugae pattern is also 
introduced in forensic identifica-
tion.6 Controversy still exists about 
the stability of quantitative and 
qualitative characteristics of rugae 
during growth and the extent of 
differences between ethnic groups 
and sexes. Another aspect of pala-
toscopy that one must consider 
is the possibility of rugae pattern 
forgery and the possible distortion 
of the palatal rugae replica as a re-
sult of poor duplicating materials 
and techniques. Further studies to 
determine the reliability of palatal 
rugoscopy in forensic identification 
are encouraged. 
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